Literature DB >> 18761661

Hippocampal sclerosis: progress since Sommer.

Maria Thom1.   

Abstract

Hippocampal sclerosis (HS) continues to be the most common pathology identified in patients with refractory temporal lobe epilepsy undergoing surgery. Wilhelm Sommer described this characteristic pattern of neuronal loss over 120 years ago through his post-mortem studies on patients with epilepsy. Neuropathological post-mortem studies in the 20th century proceeded to contribute significantly to the understanding of this disease process, with regard to the varying patterns of HS and involvement of adjacent limbic structures. From studies of surgical temporal lobe specimens from the 1950s onwards it was recognized that an early cerebral injury could act as the precipitant for the sclerosis and epilepsy. Modern neuropathological studies have focused on aspects of neuronal injury, loss of specific neuronal groups and cellular reorganization to address mechanisms of epileptogenesis and the enigma of how specific hippocampal neuronal vulnerabilities and glial proliferation are both the effect and the cause of seizures.

Entities:  

Mesh:

Year:  2008        PMID: 18761661     DOI: 10.1111/j.1750-3639.2008.00201.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  27 in total

Review 1.  Is synaptic loss a unique hallmark of Alzheimer's disease?

Authors:  Stephen W Scheff; Janna H Neltner; Peter T Nelson
Journal:  Biochem Pharmacol       Date:  2014-01-09       Impact factor: 5.858

2.  Hippocampal sclerosis in temporal lobe epilepsy: findings at 7 T¹.

Authors:  Thomas R Henry; Marie Chupin; Stéphane Lehéricy; John P Strupp; Michael A Sikora; Zhiyi Y Sha; Kâmil Ugurbil; Pierre-François Van de Moortele
Journal:  Radiology       Date:  2011-07-11       Impact factor: 11.105

3.  Inflammation in the developing rat modulates astroglial reactivity to seizures in the mature brain.

Authors:  Zuzanna Setkowicz; Emilia Kosonowska; Krzysztof Janeczko
Journal:  J Anat       Date:  2017-06-09       Impact factor: 2.610

4.  Repeated low-dose kainate administration in C57BL/6J mice produces temporal lobe epilepsy pathology but infrequent spontaneous seizures.

Authors:  Anthony D Umpierre; Isaiah V Bennett; Lismore D Nebeker; Thomas G Newell; Bruce B Tian; Kyle E Thomson; H Steve White; John A White; Karen S Wilcox
Journal:  Exp Neurol       Date:  2016-02-16       Impact factor: 5.330

5.  Hippocampal sclerosis in advanced age: clinical and pathological features.

Authors:  Peter T Nelson; Frederick A Schmitt; Yushun Lin; Erin L Abner; Gregory A Jicha; Ela Patel; Paula C Thomason; Janna H Neltner; Charles D Smith; Karen S Santacruz; Joshua A Sonnen; Leonard W Poon; Marla Gearing; Robert C Green; John L Woodard; Linda J Van Eldik; Richard J Kryscio
Journal:  Brain       Date:  2011-05       Impact factor: 13.501

Review 6.  Glial adenosine kinase--a neuropathological marker of the epileptic brain.

Authors:  Eleonora Aronica; Ursula S Sandau; Anand Iyer; Detlev Boison
Journal:  Neurochem Int       Date:  2013-02-04       Impact factor: 3.921

7.  P2X7 receptor in epilepsy; role in pathophysiology and potential targeting for seizure control.

Authors:  Tobias Engel; Alba Jimenez-Pacheco; Maria Teresa Miras-Portugal; Miguel Diaz-Hernandez; David C Henshall
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2012-12-26

Review 8.  Global expression profiling in epileptogenesis: does it add to the confusion?

Authors:  Yi Yuen Wang; Paul Smith; Michael Murphy; Mark Cook
Journal:  Brain Pathol       Date:  2009-02-24       Impact factor: 6.508

Review 9.  Rates and predictors of seizure freedom in resective epilepsy surgery: an update.

Authors:  Dario J Englot; Edward F Chang
Journal:  Neurosurg Rev       Date:  2014-02-05       Impact factor: 3.042

10.  Reduced ratio of afferent to total vascular density in mesial temporal sclerosis.

Authors:  Ryan T Mott; Clara R Thore; Dixon M Moody; Steven S Glazier; Thomas L Ellis; William R Brown
Journal:  J Neuropathol Exp Neurol       Date:  2009-10       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.